SCHEMBL21499645

SCHEMBL21499645

O=C1NC(O)Nc2ncn(Cc3ccccc3)c21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GDA Q9Y2T3 1/20 0.46
▸ CYP11B2 P19099 2/20 0.43
▸ TNF P01375 1/20 0.43
▸ CYP11B1 P15538 1/20 0.43
▸ TSHR P16473 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ PARN O95453 1/20 0.42
▸ CNOT7 Q9UIV1 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ PNP P00491 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ACP1 P24666 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ KDM4C Q9H3R0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18834819 0.75 ADORA2B (0.36) ALDH1A1KDM4EHPGD
SCHEMBL22105567 0.74 TSHR (0.45) GDACYP11B2TNFCYP11B1TSHR
SCHEMBL22105439 0.70 ALDH1A1 (0.42) GDACYP11B2TNFCYP11B1TSHR
SCHEMBL27686786 0.70 CYP11B2 (0.43) GDACYP11B2TNFCYP11B1TSHR
SCHEMBL16068380 0.68 CYP11B2 (0.54) GDACYP11B2TNFCYP11B1TSHR
SCHEMBL21499649 0.67 MAPK1 (0.43) CYP11B2CYP11B1TSHRMEN1KMT2A
SCHEMBL5745154 0.67 GDA (0.51) GDACYP11B2TNFCYP11B1TSHR
SCHEMBL23974592 0.67 TSHR (0.57) GDACYP11B2TNFCYP11B1TSHR
SCHEMBL14618904 0.67 TSHR (0.48) GDACYP11B2TNFCYP11B1TSHR
SCHEMBL30595217 0.64 PARN (0.54) CYP11B2TNFCYP11B1TSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230040259-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, LLC (US) 2023-02-09 — — US disclosed
US-11208409-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, LLC (US) 2021-12-28 — — US disclosed
US-20190322667-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230040259-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 GDA 1004/4885CYP11B2 658/4885TNF 4843/4885
US-11208409-B2 Substituted xanthines and methods of use thereof TRPC5, TRPC7, TRPC4 GDA 1004/4885CYP11B2 658/4885TNF 4843/4885
US-20190322667-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 GDA 1004/4885CYP11B2 658/4885TNF 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback